(ATN) Abbott Protease Inhibitor Lottery in January, CD4 Under 50 -- Registration Now

DonateNow
Print this article

(ATN) Abbott Protease Inhibitor Lottery in January, CD4 Under 50 -- Registration Now

AIDS TREATMENT NEWS Issue #237, December 22, 1995
John S. James


Abbott Laboratories will make its protease inhibitor ritonavir (formerly called ABT-538) available to 2,000 people worldwide, in an expanded access program starting in January. Since many more than 2,000 are expected to apply, a lottery will be used to select who gets the drug.

This program is limited to persons over the age of 12, with CD4 count under 50. There are additional medical qualifications.

Physicians and patients can obtain more information by calling 800/414-AIDS, or by fax at 800/336-2879, or by email at ritonavir@pond.com, or on the World Wide Web at http://www.pond.com/ritonavir.


951222
ATN23702


Copyright © 1995 - AIDS Treatment News. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. AIDS Treatment News, Subscription and Editorial Office: 1233 Locust St., 5th floor Philadelphia, PA 19107 800/TREAT-1-2 toll-free email: aidsnews@critpath.org  http://www.aidsnews.org

Subscription Information: Call 800/TREAT-1-2: Businesses, Institutions, Professionals: $270/year. Includes early delivery of an extra copy by email. Nonprofit organizations: $135/year. Includes early delivery of an extra copy by email. Individuals: $120/year, or $70 for six months. Special discount for persons with financial difficulties: $54/year, or $30 for six months. If you cannot afford a subscription, please write or call. Outside North, Central, or South America, add air mail postage: $20/year, $10 for six months. Back issues available. Fax subscriptions, bulk rates, and multiple subscriptions are available; contact our office for details. Please send U.S. funds: personal check or bank draft, international postal money order, or travelers checks. VISA, Mastercard, and purchase orders also accepted. ISSN # 1052-4207

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .